• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Tesla, Ra Medical Systems And 51 Stocks Moving In Tuesday's Mid-Day Session

    7/5/22 12:05:48 PM ET
    $AEG
    $ALNA
    $AMLX
    $ANEB
    Life Insurance
    Finance
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AEG alert in real time by email

    Gainers

    • Ra Medical Systems, Inc. (NASDAQ:RMED) shares jumped 69.6% to $0.5240 after the company announced it has received FDA 510(k) clearance for its DABRA 2.0 catheter.
    • Rubicon Technology, Inc. (NASDAQ:RBCN) shares jumped 64% to $14.84 after the company announced that it entered into a definitive stock purchase and sale agreement with Janel Corporation.
    • Maris-Tech Ltd. (NASDAQ:MTEK) gained 50% to $1.74 after the company received a purchase order from SpaceIL for the development of a video recording, streaming and image processing solution for the Beresheet 2 Lunar Mission.
    • ZW Data Action Technologies Inc. (NASDAQ:CNET) climbed 47% to $0.4990.
    • Faraday Future Intelligent Electric Inc. (NASDAQ:FFIE) shares rose 33.6% to $4.7420 after jumping over 36% on Friday.
    • Onion Global Limited (NYSE:OG) surged 32.8% to $1.13. Onion Global generated more than RMB14.8 million in GMV within the first three days of its 2022 Luca Brand Shopping Festival.
    • Alpha Tau Medical Ltd. (NASDAQ:DRTS) gained 30% to $9.84 after dropping 16% on Friday.
    • Cowen Inc. (NASDAQ:COWN) rose 24.5% to $29.93.
    • Uxin Limited (NASDAQ:UXIN) gained 22.8% to $0.5528. Uxin recently announced entry into definitive agreements for financing transaction of $100 million in replacement of the previously announced binding term sheet.
    • Avadel Pharmaceuticals plc (NASDAQ:AVDL) surged 19.8% to $3.08. Avadel Pharmaceuticals recently announced its steps to explore every available pathway to accelerate the FDA approval of its lead drug candidate, FT218, before June 2023.
    • Cognition Therapeutics, Inc. (NASDAQ:CGTX) gained 19.6% to $2.6899. Cognition Therapeutics recently dosed first patient in the SHIMMER study of lead drug CT1812, an experimental, orally delivered small molecule therapeutic intended to address the underlying biology of dementia with Lewy bodies (DLB).
    • bluebird bio, Inc. (NASDAQ:BLUE) gained 19.3% to $5.11.
    • Tyme Technologies, Inc. (NASDAQ:TYME) jumped 19.3% to $0.3225. Syros Pharmaceuticals has agreed to acquire TYME Technologies, including its pipeline assets and net cash, after accounting for wind-down and transaction expenses currently estimated to be approximately $60 million.
    • Dyne Therapeutics, Inc. (NASDAQ:DYN) gained 17% to $8.43 after the company announced FDA clearance of its Investigational New Drug application for DYNE-251 for the treatment of Duchenne muscular dystrophy.
    • Athenex, Inc. (NASDAQ:ATNX) surged 16.4% to $0.5038.
    • Symbotic Inc. (NASDAQ:SYM) gained 16.4% to $13.84. Raymond James initiated coverage on Symbotic with an Outperform rating and announced a price target of $18.
    • Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) surged 15.5% to $22.49. Amylyx Pharmaceuticals announced FDA plan to reconvene the advisory committee to review AMX0035 NDA for the treatment of ALS on September 7, 2022.
    • Precigen, Inc. (NASDAQ:PGEN) gained 15.6% to $1.6307 after the company agreed to sell its subsidiary Trans Ova Genetics to URUS for $170 million in upfront cash.
    • Talaris Therapeutics, Inc. (NASDAQ:TALS) rose 15.2% to $2.65. Morgan Stanley downgraded Talaris Therapeutics from Overweight to Equal-Weight and announced an $8 price target.
    • Blue Star Foods Corp. (NASDAQ:BSFC) surged 15.1% to $1.37.
    • DIRTT Environmental Solutions Ltd. (NASDAQ:DRTT) gained 14.5% to $1.2599.
    • NewAge, Inc. (NASDAQ:NBEV) gained 13.6% to $0.2653. NewAge, last month, reported a review of strategic alternatives.
    • Mercurity Fintech Holding Inc. (NASDAQ:MFH) jumped 13.6% to $0.7950.
    • Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) gained 12.4% to $0.6555.
    • OneConnect Financial Technology Co., Ltd. (NASDAQ:OCFT) rose 10.8% to $2.05. OneConnect successfully listed on the Main Board of The Stock Exchange of Hong Kong Limited.
    • Tupperware Brands Corporation (NYSE:TUP) gained 10.7% to $7.42.
    • Scopus BioPharma Inc. (NASDAQ:SCPS) rose 9.7% to $0.4368 after declining over 7% on Friday.
    • Soleno Therapeutics, Inc. (NASDAQ:SLNO) rose 9.4% to $0.1958 after dropping over 3% on Friday.
    • Offerpad Solutions Inc. (NYSE:OPAD) rose 7.4% to $2.3850.


    Losers

    • Kalera Public Limited Company (NASDAQ:KAL) shares fell 20.8% to $2.86 after tumbling 39% on Friday.
    • Staffing 360 Solutions, Inc. (NASDAQ:STAF) dipped 20.4% to $4.92. Staffing 360 Solutions reported a $4 million private placement priced at-the-market under Nasdaq rules.
    • Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) declined 20.4% to $0.4880.
    • Nemaura Medical Inc. (NASDAQ:NMRD) declined 20.2% to $2.0501. Nemaura Medical reported its Q4 earnings results on Thursday, June 30, 2022.
    • Miromatrix Medical Inc. (NASDAQ:MIRO) declined 19.8% to $2.6472. Miromatrix applauded the FDA for its continued commitment to the field of organ transplant.
    • Revelation Biosciences, Inc. (NASDAQ:REVB) dropped 19.4% to $0.8380.
    • Omeros Corporation (NASDAQ:OMER) declined 18.4% to $3.7850.
    • Harte Hanks, Inc. (NASDAQ:HHS) fell 17.7% to $10.35. Harte Hanks recently announced an agreement to repurchase preferred shares from Wipro.
    • Augmedix, Inc. (NASDAQ:AUGX) dropped 17.7% to $1.63.
    • Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) fell 16.3% to $0.1775. Allena Pharmaceuticals announced rescheduling of special meeting to approve reverse stock split.
    • Mega Matrix Corp. (NYSE:MTMT) declined 15.7% to $1.44.
    • PARTS iD, Inc. (NYSE:ID) fell 14.7% to $1.27.
    • Clovis Oncology, Inc. (NASDAQ:CLVS) fell 14.4% to $2.4397.
    • Redbox Entertainment Inc. (NASDAQ:RDBX) dropped 14.3% to $5.24.
    • Unico American Corporation (NASDAQ:UNAM) declined 12.9% to $1.75.
    • Usio, Inc. (NASDAQ:USIO) fell 12.2% to $2.1071. Usio’s CEO provided a business update today.
    • Engine Gaming and Media, Inc. (NASDAQ:GAME) fell 11.7% to $0.8020. Engine Gaming and Media is expected to release fiscal third quarter results on Thursday, July 14, 2022.
    • Cryptyde, Inc. (NASDAQ:TYDE) shares fell 10.9% to $1.2399 after dipping around 32% on Friday.
    • Aegon N.V. (NYSE:AEG) fell 10.5% to $4.0150.
    • WPP plc (NYSE:WPP) shares fell 9.6% to $45.50. WPP recently announced plans to acquire Bower House Digital.
    • Fast Radius, Inc. (NASDAQ:FSRD) fell 9.4% to $0.8050 after jumping 41% on Friday. Fast Radius, last month, appointed Pat McCusker as President, Interim CFO and John Nanry as COO.
    • Austin Gold Corp. (NYSE:AUST) shares fell 9.3% to $1.65.
    • Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) fell 5.2% to $5.09. Anebulo Pharmaceuticals announced positive topline data from Part A of an ongoing Phase 2 clinical trial of its drug candidate ANEB-001 for patients with acute cannabinoid intoxication (ACI).
    • Tesla, Inc. (NASDAQ:TSLA) fell 3% to $661.75 following bearish analyst coverage from JPMorgan. JPMorgan analyst Ryan Brinkman maintained Tesla with an Underweight rating and lowered the price target from $395 to $385, citing weaker-than-expected deliveries.
    Get the next $AEG alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AEG
    $ALNA
    $AMLX
    $ANEB

    CompanyDatePrice TargetRatingAnalyst
    Tesla Inc.
    $TSLA
    3/4/2026$460.00Buy
    BofA Securities
    Alpha Tau Medical Ltd.
    $DRTS
    3/4/2026$5.00Overweight → Neutral
    Piper Sandler
    Amylyx Pharmaceuticals Inc.
    $AMLX
    3/3/2026$21.00Buy
    Stifel
    WPP plc
    $WPP
    2/27/2026Underweight → Equal Weight
    Barclays
    Tesla Inc.
    $TSLA
    2/12/2026$550.00Buy
    Tigress Financial
    Tesla Inc.
    $TSLA
    1/30/2026$150.00 → $145.00Underweight
    Analyst
    Tesla Inc.
    $TSLA
    1/12/2026$120.00 → $130.00Underweight
    Wells Fargo
    WPP plc
    $WPP
    1/12/2026Neutral
    Citigroup
    More analyst ratings

    $AEG
    $ALNA
    $AMLX
    $ANEB
    SEC Filings

    View All

    SEC Form 6-K filed by WPP plc

    6-K - WPP plc (0000806968) (Filer)

    3/10/26 2:55:42 PM ET
    $WPP
    Advertising
    Consumer Discretionary

    SEC Form S-8 filed by Alpha Tau Medical Ltd.

    S-8 - Alpha Tau Medical Ltd. (0001871321) (Filer)

    3/9/26 5:01:21 PM ET
    $DRTS
    Medical/Dental Instruments
    Health Care

    SEC Form 20-F filed by Alpha Tau Medical Ltd.

    20-F - Alpha Tau Medical Ltd. (0001871321) (Filer)

    3/9/26 4:03:11 PM ET
    $DRTS
    Medical/Dental Instruments
    Health Care

    $AEG
    $ALNA
    $AMLX
    $ANEB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Posner Brian S bought $45,180 worth of shares (3,000 units at $15.06), increasing direct ownership by 35% to 11,500 units (SEC Form 4)

    4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)

    3/10/26 5:33:53 PM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner National Services, Inc bought $411,562 worth of shares (198,232 units at $2.08) and sold $44,498 worth of shares (31,897 units at $1.40), increasing direct ownership by 6% to 2,813,172 units (SEC Form 4)

    4 - Usio, Inc. (0001088034) (Issuer)

    12/29/25 6:08:22 AM ET
    $USIO
    Investment Bankers/Brokers/Service
    Finance

    Director Firestone Karen bought $100,845 worth of shares (8,100 units at $12.45), increasing direct ownership by 15% to 63,100 units (SEC Form 4)

    4 - Amylyx Pharmaceuticals, Inc. (0001658551) (Issuer)

    12/23/25 8:48:33 PM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AEG
    $ALNA
    $AMLX
    $ANEB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BofA Securities resumed coverage on Tesla with a new price target

    BofA Securities resumed coverage of Tesla with a rating of Buy and set a new price target of $460.00

    3/4/26 8:40:18 AM ET
    $TSLA
    Auto Manufacturing
    Industrials

    Alpha Tau downgraded by Piper Sandler with a new price target

    Piper Sandler downgraded Alpha Tau from Overweight to Neutral and set a new price target of $5.00

    3/4/26 8:30:52 AM ET
    $DRTS
    Medical/Dental Instruments
    Health Care

    Stifel initiated coverage on Amylyx Pharmaceuticals with a new price target

    Stifel initiated coverage of Amylyx Pharmaceuticals with a rating of Buy and set a new price target of $21.00

    3/3/26 8:26:33 AM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AEG
    $ALNA
    $AMLX
    $ANEB
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    December 8, 2023 - FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease

    For Immediate Release: December 08, 2023 Today, the U.S. Food and Drug Administration approved two milestone treatments, Casgevy and Lyfgenia, representing the first cell-based gene therapies for the treatment of sickle cell disease (SCD) in patients 12 years and older. Additionally, one of these therapies, Casgevy, is the first FDA-approved treatment to utilize a type of novel genome editing technology, signali

    12/8/23 11:12:21 AM ET
    $BLUE
    $VRTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    FDA Approval for RUBRACA issued to CLOVIS ONCOLOGY INC

    Submission status for CLOVIS ONCOLOGY INC's drug RUBRACA (SUPPL-13) with active ingredient RUCAPARIB CAMSYLATE has changed to 'Approval' on 12/21/2022. Application Category: NDA, Application Number: 209115, Application Classification: Efficacy

    12/22/22 4:37:40 AM ET
    $CLVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    September 29, 2022 - FDA Approves New Treatment Option for Patients with ALS

    For Immediate Release: September 29, 2022 The U.S. Food and Drug Administration today approved Relyvrio (sodium phenylbutyrate/taurursodiol) to treat patients with amyotrophic lateral sclerosis (ALS), commonly referred to as Lou Gehrig’s disease.  “This approval provides another important treatment option for ALS, a life-threatening disease that currently has no cure,” said Billy Dunn, M.D., director of the Off

    9/29/22 5:02:14 PM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AEG
    $ALNA
    $AMLX
    $ANEB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Alpha Tau Announces Full Year 2025 Financial Results and Provides Corporate Update

    - Tremendous activity in recent months, including receipt of Japanese marketing approval, the fifth parallel U.S. trial approval, data from pancreatic cancer trials presented at ASCO GI Symposium, and the first brain cancer treatment - - Multiple meaningful milestones targeted in the coming months, including completion of patient recruitment in the U.S. pivotal ReSTART skin cancer trial, in the U.S. pilot IMPACT pancreatic cancer trial, and in the U.S. recurrent glioblastoma multiforme feasibility trial - - $76.9 million in cash, cash equivalents & deposits provides continued balance sheet strength for clinical advancement and commercial preparation - JERUSALEM, March 09, 2026 (GLOBE NE

    3/9/26 4:02:00 PM ET
    $DRTS
    Medical/Dental Instruments
    Health Care

    Moonage Media with Defense Sector Trends in 2026: The Rise of Edge AI, Autonomous Drones, and Real-Time Battlefield Intelligence - And Why Maris-Tech's Technology Is the Answer to This Market Need

    HONG KONG, March 9, 2026 /PRNewswire/ -- The global defense landscape in 2026 is undergoing rapid transformation, driven by escalating geopolitical tensions, lessons from ongoing conflicts (notably in Ukraine and the Middle East), and massive increases in military budgets. Global defense spending is projected to exceed $2.6 trillion this year, with significant portions funneled into unmanned systems, AI integration, autonomous platforms, and edge computing to enable faster, more resilient decision-making in contested environments. Key trends dominating the sector include:Explosion in Unmanned and Autonomous Systems — Drones, loitering munitions (kamikaze drones), and tactical UAVs have prove

    3/9/26 9:27:00 AM ET
    $MTEK
    Telecommunications Equipment
    Telecommunications

    Maris-Tech Signs Deal for Integration into "Kamikaze" Drones: Moonage Media Explains Why This Shouldn't Surprise Anyone

    HONG KONG, March 9, 2026 /PRNewswire/ -- Maris-Tech Ltd. (NASDAQ:MTEK) is an Israeli technology company founded in 2008. The company designs, develops, manufactures, and sells compact digital video and audio products, with a focus on edge AI-accelerated solutions for real-time video processing and streaming. Its technologies are used mainly in defense, homeland security, unmanned systems, tactical platforms as well as incommercial applications, where low latency, low power consumption, and small size are critical requirements. Last month, on February 19, 2026, Maris-Tech announced its first significant production order for the Jupiter Drone edge video processing system – not from just any cu

    3/9/26 8:54:00 AM ET
    $MTEK
    Telecommunications Equipment
    Telecommunications

    $AEG
    $ALNA
    $AMLX
    $ANEB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Posner Brian S bought $45,180 worth of shares (3,000 units at $15.06), increasing direct ownership by 35% to 11,500 units (SEC Form 4)

    4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)

    3/10/26 5:33:53 PM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Taneja Vaibhav converted options into 6,538 shares and sold $899,077 worth of shares (2,264 units at $397.03), increasing direct ownership by 31% to 18,106 units (SEC Form 4)

    4 - Tesla, Inc. (0001318605) (Issuer)

    3/9/26 7:00:14 PM ET
    $TSLA
    Auto Manufacturing
    Industrials

    SVP, Chief Product Officer Frost Houston Korth exercised 4,000 shares at a strike of $1.34, increasing direct ownership by 0.56% to 721,108 units (SEC Form 4)

    4 - Usio, Inc. (0001088034) (Issuer)

    3/9/26 4:53:53 PM ET
    $USIO
    Investment Bankers/Brokers/Service
    Finance

    $AEG
    $ALNA
    $AMLX
    $ANEB
    Leadership Updates

    Live Leadership Updates

    View All

    Soleno Therapeutics Announces Retirement of James Mackaness and Appointment of Jennifer Fulk as Chief Financial Officer

    REDWOOD CITY, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the appointment of Jennifer Fulk as Chief Financial Officer, succeeding James Mackaness, who announced that he will be retiring from the Company by the end of the first quarter. Mr. Mackaness will serve as a consultant to Soleno through the end of the year to ensure a smooth transition. Mrs. Fulk brings to Soleno more than two decades of public company experience in leading financial strategy, investor relations, financial reporting, and operational efficiency, with a diverse c

    2/26/26 8:00:00 AM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Offerpad Appoints Tela Gallagher Mathias to Board of Directors

    Offerpad Solutions Inc. (NYSE:OPAD) today announced appointment of Tela Gallagher Mathias to its Board of Directors. Mathias will serve on the company's Audit Committee and Compensation Committee, further strengthening governance oversight as Offerpad accelerates its AI strategy and scales its multi-solution real estate operating model. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260217840736/en/Tela Gallagher Mathias, Offerpad Board Member Mathias brings more than 25 years of experience designing and deploying enterprise technology platforms across mortgage, housing finance, and regulatory environments, with deep expertise i

    2/17/26 9:03:00 AM ET
    $OPAD
    Real Estate
    Finance

    Offerpad Appoints Dr. Jai Singh as Chief Pricing and Analytics Officer to Lead AI-Driven Pricing and Portfolio Strategy

    Offerpad Solutions Inc. (NYSE:OPAD) today announced the appointment of Dr. Jai Singh as Chief Pricing and Analytics Officer, reflecting an expanded mandate to accelerate the company's AI-driven pricing, portfolio management, and marketing optimization initiatives as Offerpad continues to scale its multi-solution real estate platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260203766199/en/Dr. Jai Singh - Offerpad Chief Pricing and Analytics Officer Dr. Singh has extensive financial and analytical leadership experience, with a background spanning senior roles across investment management and global financial services organ

    2/3/26 9:05:00 AM ET
    $OPAD
    Real Estate
    Finance

    $AEG
    $ALNA
    $AMLX
    $ANEB
    Financials

    Live finance-specific insights

    View All

    Usio to Host Fourth Quarter and Fiscal Year End 2025 Conference Call to Discuss Results and Provide Company Update on March 18, 2026

    SAN ANTONIO, March 04, 2026 (GLOBE NEWSWIRE) -- Usio, Inc. (NASDAQ:USIO), a leading provider of integrated, cloud-based electronic payment and embedded financial solutions, today announced it will release financial results for the fourth quarter and fiscal year ended December 31, 2025, after the market closes on Wednesday, March 18, 2026. Usio's management will host a conference call the same day, March 18, 2026, beginning at 4:30 p.m. Eastern time to review financial results and provide a business update. Following management's formal remarks, there will be a question-and-answer session. To listen to the conference call, interested parties within the U.S. should call 1-844-883-3890. Int

    3/4/26 9:05:00 AM ET
    $USIO
    Investment Bankers/Brokers/Service
    Finance

    Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results

    Recruitment of the pivotal Phase 3 LUCIDITY trial of avexitide in PBH is complete; continue to expect to randomize and dose last eligible participants in Q1 2026, with topline data anticipated in Q3 2026 Cash runway expected to fund operations through potential avexitide commercialization and into 2028 Management to host conference call and webcast today at 8:00 a.m. Eastern Time Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") today reported financial and business results for the fourth quarter and full year ended December 31, 2025. "2025 was a year of meaningful advancement for Amylyx's pivotal avexitide program in post-bariatric hypoglycemia, as well as

    3/3/26 7:00:00 AM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Soleno Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Update on U.S. Launch of VYKAT™ XR

    REDWOOD CITY, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today reported financial results for the fourth quarter and full-year ended December 31, 2025 and provided an update on the U.S. launch of VYKAT™ XR (diazoxide choline) extended-release tablets. Fourth Quarter and Full-Year 2025 and Recent Corporate Highlights Revenue, net, from the sale of VYKAT XR for the three and twelve months ended December 31, 2025, was $91.7 million and $190.4 million, respectively.From approval on March 26, 2025 through December 31, 2025, Soleno reports: 1,250 patien

    2/25/26 4:01:00 PM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $AEG
    $ALNA
    $AMLX
    $ANEB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Maris-Tech Ltd.

    SC 13G/A - Maris Tech Ltd. (0001872964) (Subject)

    12/13/24 11:34:57 AM ET
    $MTEK
    Telecommunications Equipment
    Telecommunications

    SEC Form SC 13D filed by Harte Hanks Inc.

    SC 13D - HARTE HANKS INC (0000045919) (Subject)

    12/6/24 6:51:56 PM ET
    $HHS
    Advertising
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Maris-Tech Ltd.

    SC 13G/A - Maris Tech Ltd. (0001872964) (Subject)

    11/27/24 10:44:51 AM ET
    $MTEK
    Telecommunications Equipment
    Telecommunications